Peter C. Adamson, MD

As chair of the Children's Oncology Group (COG), Dr. Adamson is in constant contact with leading pediatric cancer researchers across the country who are hard at work on the most promising new therapies.

Areas of Expertise: Investigational new drugs for childhood cancer
Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP

  • Background

    Creating disease-targeted therapies for children with cancer requires a better pathway for moving from the bench to the bedside.

    As the recently selected chair of the Children's Oncology Group (COG), a group of more 200 centers that brings together 5,000 international experts in childhood cancer, I am in constant contact with leading researchers across the country. There are great opportunities ahead to improve the outcome for children with cancer, and we are hard at work trying to speed the timeline so the most promising new therapies can move forward. We are working on creating better pathways for disease-targeted therapies for children with cancer, and are focusing our efforts on transforming how new discoveries can move from the bench to the bedside, a process called translational research.

    For more than eight years I led a group of 21 institutions that performed the initial evaluation of new drugs for children with cancer. We conducted more than 25 Phase I studies; these studies are the first clinical trials of new anticancer drugs in children whose cancer has recurred despite best-known treatments. I thus have direct knowledge of the investigational new drug trials being conducted not only at Children's Hospital, but at centers worldwide. This allows me to serve as a resource on experimental cancer treatment for Children's Hospital clinicians. For the child whose cancer has recurred, these are the kinds of trials they often seek out.

    Even though we have come a long way in our ability to cure children with many types of cancer, we must still strive to find cures for all children. We also must develop treatments that have fewer side effects. Together with the COG, doctors at Children's Hospital are helping to lead the way in this effort.

     

  • Education and Training

    Medical School

    MD - Cornell University Medical College, New York, NY

    Residency

    Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA

    Fellowship

    National Cancer Institute, Washington, DC

    Board Certification

    Pediatrics
    Pediatric Hematology-Oncology
    Clinical Pharmacology

  • Titles and Academic Titles

    Chief, Division of Clinical Pharmacology and Therapeutics

    Director, Experimental Therapeutics in Oncology

    Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Centers and Programs
  • Research Interests
  • Publications

    Books

    Chapters

    2010

    Widemann BC, Adamson PC. Fundamentals of Cancer Chemotherapy. In: Carroll WL, Finlay JL, editors. Cancer in Children and Adolescents. Boston: Jones and Bartlett; 2010. p. 95-112.

    2008

    Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: Revolution or evolution? Eur J Cancer. 2008 Jan;44(1):8-11.

    Abstracts

    2009

    Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, et al. Phase I study of sorafenib in children with refractory solid tumors: a Children's Oncology Group phase I consortium trial [abstract]. ASCO Meeting Abstracts; 2009 May 20, 2009;27(15S):10012-.

    Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, et al. Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: a Children's Oncology Group phase I consortium study [abstract]. ASCO Meeting Abstracts; 2009 May 20, 2009;27(15S):10017-.

    Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT Jr, et al. A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: a Children's Oncology Group phase I consortium study [abstract]. ASCO Meeting Abstracts; 2009 May 20, 2009;27(15S):10013-.

    Papers

    2010

    Su F, Nicolson SC, Gastonguay MR, Barrett JS, Adamson PC, Kang DS, et al. Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg. 2010 May 1;110(5):1383-92. Cited in PubMed: PMID 20418300.  Read the article

    Norris RE, Adamson PC. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias. Cancer Chemother Pharmacol. 2010 May;65(6):1125-30. Epub 2009 Sep 27. Cited in PubMed: PMID 19784838.  Read the abstract

    Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, et al. Pediatric phase I trial and pharmacokinetic study of Vorinostat: A Children's Oncology Group phase I consortium report. J Clin Oncol. 2010 Jul 6. Cited in PubMed: PMID 20606092. Read the abstract

    Lipsitz E, Moorthy G, Mosse Y, Fox E, Adamson PC. A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2369-73. Epub 2010 Jul 3. Read the abstract.

    Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, et al. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomi VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. Pediatr Blood Cancer. 2010 Apr;54(4):538-45. Read the abstract

    Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, et al. Days in children and young adults with refractory solid tumors: a report from the Children's Oncology Group. Clin Cancer Res. Epub 2010 Jan 12. Read the abstract

    Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol. 2010 Sep;66(4):737-43. Epub 2010 Jan 1. Read the abstract

    Mondick J, Johnson B, Haberer L, Sale M, Adamson P, Coté C, et al. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months. Eur J Clin Pharmacol. [10.1007/s00228-009-0730-8]. 2010;66(1):77-86. Read the abstract

    Posters and Presentations

    2009

    Adamson P. Cancer drug development: 21st century science, 20th century clinical trials [grand rounds]. Texas Children's Cancer Center; 2009 Jan 22; Houston.

  • Editorial and Academic Positions

    Editorial positions

    Editorial board

    Journal of Clinical Oncology
    Pediatric Blood & Cancer
    Pediatric Hematology and Oncology

    Reviewer

    Blood
    Cancer
    Cancer Chemotherapy and Pharmacology
    Cancer Research
    Clinical Cancer Research
    Journal of Pediatric Hematology/Oncology
    Journal of the National Cancer Institute
    Leukemia
    Leukemia Research 

    Academic positions

    2007-present, CHOP Task Force on Industrial Relations Policy
    CHOP Research Subject Recruitment Committee
    CHOP Grants & Contracts Compliance Sub-committee
    CHOP Research Compliance Oversight Committee